"On the one hand, there is the innovation that costs, with the progressive number of high-cost drugs that must be brought to the patient's bed, and on the other hand, the need to make the health system financially sustainable. The two things are not as an alternative: we must ensure innovation that is true innovation and not just a simple novelty." Giovanni Pavesi, administrative director of the Italian Agency of the drug (Aifa) said, intervenin…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
"On the one hand, there is the innovation that costs, with the progressive number of high-cost drugs that must be brought to the patient's bed, and on the other hand, the need to make the health system financially sustainable. The two things are not as an alternative: we must ensure innovation that is true innovation and not just a simple novelty." Giovanni Pavesi, administrative director of the Italian Agency of the drug (Aifa) said, intervenin…